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ORIGINAL ARTICLE
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ABSTRACT
The goal of periodontal therapy includes management of bacterial pathogens to control the destruction of the
periodontal tissue. A number of different nonsurgical and surgical therapies have been used in achieving this goal.
Objective: To evaluate the effectiveness of doxycycline compared with nonsurgical therapy alone or in combination
with nonsurgical therapy on gingival crevicular fluid β-Glucuronidase levels (ßG) and clinical parameters over a
20-week period in patients with chronic periodontitis. Methods: An interventional study comprising 60 patients
with chronic periodontitis. They were divided into three groups of different treatment approach. The plaque index,
gingival index, probing depth, and clinical attachment levels were recorded, and gingival crevicular fluid (GCF)
samples were collected at 2, 6, 10, and 20 weeks, after treatment. Results: The levels of GCF βG and clinical
parameters were higher when the treatment was initiated, and the levels decreased after treatment. No significant
difference was found in the βG level when nonsurgical therapy and doxycycline were used alone. In comparison,
when doxycyline and nonsurgical therapy were combined, the level of βG decreased significantly. Conclusion: The
present study indicated the usefulness of doxycycline as an adjunct to nonsurgical periodontal therapy in lowering
GFC βG levels and clinical parameters.
Keywords: doxycycline; periodontitis; β-Glucuronidase; gingival crevicular fluid; nonsurgical periodontal
therapy
How to cite this article: Afaf Zia, Afshan Bey, Asad U Khan, Saif Khan, Rosina Khan, Mohd Adil. The Effect of
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Dent Indones. 2017;24(2):38-44

INTRODUCTION

Bacterial virulence factors either result directly in
degradation of host tissues or cause the release of
biologic mediators from host tissue cells that lead
to host tissue destruction. The mediators that are
produced as a part of the host response that contributes
to tissue destruction include proteinases, cytokines,
and prostaglandins, as well as a variety of enzymes
produced by periodontal microorganisms that cause
tissue destruction.1

Periodontitis is a disease characterized by the loss
of connective tissue attachment and bone around the
teeth in conjunction with the formation of periodontal
pockets due to the apical migration of the junctional
epithelium.1 The microbial nature of many periodontal
diseases has been recognized for a long time. More
recently, it has been realized that host-related factors
may be the keys for understanding the disease
processes. Periodontal disease progression is episodic
in nature on the tooth-site level; however, the risk of
developing periodontal disease is principally patient
based rather than site based.2

The early diagnosis and treatment of progressive
periodontitis is important because of the irreversible
n at u re of t h is d ise a se. 3 Tr a d it ion al cl i n ical
measurements (probes of the pocket depth, blood loss
38
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upon probing, clinical attachment loss, plaque index,
and radiographs) used for periodontal diagnosis are
often of limited usefulness in that they are indicators of
previous periodontal disease rather than present disease
activity.4 New diagnostic tests need to be developed
that can detect the presence of active disease, predict
future disease progression and evaluate the response
to periodontal therapy, thereby improving the clinical
management of periodontal patients. Advances in
oral and periodontal disease diagnostic research are
moving toward methods whereby periodontal risk can
be identified and quantified by objective measures,
such as biomarkers.5
ß glucuronidase (ßG) ia a lysosomal enzyme that
degrades proteoglycans and ground substance and
are released from the azurophilic (primary) granules
of PMNs in response to stimuli such as N-formylmethionyl-leucyl-phenylalanine, platelet-activating
factor, anaphylotoxin C5a, LTB4, and IL8 — serves
as a marker in periodontitis.6,7 ß glucuronidase is
a glycoprotein of about 332,000 Dalton.6-8 It is a
homotetramer comprised of four identical subunits.
βG, together with hyaluronidase, is involved in the
catabolism of proteoglycans. The endoglycosidase
hyaluronidase cleaves hexosaminidic linkages,
producing tetrasaccharides. This tetrasaccharide is
further degraded by βG and β-N-acetylhexosaminidase.
Therefore, βG most likely contributes to noncollagenous matrix degradation in periodontal
diseases.8
The relationship between βG activity and periodontal
disease has clearly been shown.8 Furthermore, βG
activity may be a good indicator or predictor of
periodontal disease activity, and its potential for
indicating primary granular release from PMNs has
been observed. It has high sensitivity and specificity
when related to occurrence of clinical attachment loss.
This enzyme has also proved to be a good predictor
of the response to treatment and the risk for future
periodontal breakdown.9 Increased levels of βG in GCF
have been associated with increased risk for periodontal
attachment loss in systemically healthy individuals
and are strongly correlated with probing depth (PD).
However, decreased levels of βG in GCF have been
linked with conservative periodontal therapy.2,10
The essential goal of periodontal therapy is the
successful management of bacterial pathogens to
the extent that destruction of the periodontium is
arrested. A number of different nonsurgical and
surgical therapies have been successful in achieving
this goal.11-13 The primary nonsurgical approach
involves mechanical scaling and root planing (SRP).
The beneficial effects of SRP arise from a reduction
in the microbial burden in the periodontal pocket, or
a shift toward less pathogenic microflora.14 However,
the efficacy of SRP may be compromised at tooth sites
with deep periodontal pockets. Furthermore, the long-

term success of SRP may be affected by the remaining
bacterial virulence factors and ineffective personal
plaque control.12
Several antimicrobial agents have been attempted
systemically as an adjunct to the mechanical treatment
of periodontal disease.15 Systemic antibiotics may
be used to reduce the bacterial load and to enhance
the host’s defense to infectious pathogens in chronic
periodontitis. Tetracycline, metronidazole, and
amoxicillin are among the antibiotics used in the
treatment of periodontal disease, and their use is
determined based on a patient’s medical and dental
history, disease diagnosis, and the possible side effects.
Also, doxycycline is a potentially valuable antibiotic,
with a broad spectrum of activity. Doxycycline has
the capability of conditioning dentine and also enables
fibrin linkage, both of which favor the formation of
new attachment.16,17 Doxycycline potentiates osseous
regeneration in periodontal defects due to its anticollagenase activity.18
The purpose of this interventional study was to
evaluate the efficacy of systemic doxycycline alone or
in combination with nonsurgical periodontal therapy
compared with nonsurgical periodontal therapy and
the impact on the GCF β-glucuronidase levels and
clinical parameters of patients with similar chronic
periodontitis severity.19

METHODS
Study design
The present study was conducted in the Department of
Periodontics, Dr Z. A. Dental College, AMU, Aligarh.
The Institutional Ethics Committee of the Faculty of
Medicine provided approval for the study. This was
a randomized, interventional study in subjects with
chronic periodontitis. The clinical trial extended over
a 20-week period and was designed as a double-blind
study.
Study population
A total of 60 untreated chronic adult periodontitis
patients (consisting of 22 males and 38 females), aged
25 and over, were recruited from new referrals to the
OPD of Department of Periodontics and Community
Dentistry, Dr. Z. A. Dental College and Hospital,
A.M.U., Aligarh. Informed consent was obtained from
all the patients.
Inclusion criteria
The subjects included in this study were having no
history of systemic disorders/smoking, no history of
antibiotics and anti-inflammatory drugs within the past
6 months, and no history of any dental treatment within
the past 6 months. The subjects must have at least 20
teeth remaining in the mouth and at least had five
sites with > 4mm pocket depth. Following a baseline
39
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Table 1. Clinical parameters measurement of all groups of treatment
GROUPS
BASELINE
Plaque Index
1
1.36 ± 0.91
2
1.65 ± 0.18
3
1.64 ± 0.16
Gingival Index
1
1.63 ± 0.26
2
1.63 ± 0.29
3
1.49 ± 0.25
Probing Depth (mm)
1
4.69 ± 0.53
2
3.91 ± 0.65
3
3.93 ± 0.92
Clinical Attachment Level (mm)
1
6.63 ±0.35
2
6.34 ± 0.19
3
5.31 ± 0.46

2

TIME (weeks)
6

10

20

0.87 ± 0.13
1.43 ± 0.26
0.73 ± 0.11

0.78 ± 0.08
1.4 ± 0.25
0.65 ± 0.18

0.68 ± 0.35
1.34 ± 0.31
0.55 ± 0.18

0.79 ± 0.25
1.64 ± 0.122
0.56 ± 0.25

0.91 ± 0.22
0.63 ± 0.19
0.67 ± 0.16

0.79 ± 0.19
0.57 ± 0.21
0.61 ± 0.15

0.76 ± 0.19
0.74 ± 0.18
0.53 ± 0.17

0.77 ± 0.18
1.45 ± 0.34
0.60 ± 0.19

2.4 ± 0.6
3.46 ± 0.83
1.79 ± 0.85

1.09 ± 0.3
3.37 ± 0.74
1.27 ± 0.21

0.89 ± 0.27
3.48 ± 0.69
0.99 ± 0.19

0.75 ± 0.47
3.78 ± 1.14
1.09 ± 0.44

3.43 ± 0.25
5.28 ± 0.51
3.34 ± 0.55

2.91 ± 0.17
4.88 ± 0.43
3.14 ± 0.28

2.85 ± 0.13
4.92 ± 0.47
2.77 ± 0.37

2.45 ± 0.31
5.2 ± 0.80
2.96 ± 0.38

Group 1 = scaling and root planing; Group 2= systemic doxycycline; Group 3= systemic doxycycline with scaling and root
planing. Differences of the clinical parameters measurement are shown in in mean ± SD.

examination, the patients were randomly distributed
into three groups of 20 members each. The patients
in the first group were meticulously treated by SRP.
The second group received systemically administered
doxycycline from the first appointment at a dosage of
100 mg/ day for 14 days, with a loading dose of 200 mg
on the first day. The third group of patients received
systemically administered doxycycline from the first
appointment at a dosage of 100mg/ day for 14 days,
with a loading dose of 200mg on the first day along
with SRP.

excluding third molars at the baseline and after 2, 6,
10, and 20 weeks.
Collection of GCF
The sites selected randomly were air-dried and
isolated with cotton rolls to exclude contamination
with saliva, and the crown of the tooth was gently
cleaned to remove supragingival plaque. The GCF was
collected by inserting absorbent paper points into the
gingival sulcus for 30s, avoiding any bleeding from the
marginal gingiva.23 The paper points that were visibly
contaminated with blood were discarded. To eliminate
the risk of evaporation, the paper points were placed
immediately in 1.5ml Eppendorf vials containing a
buffer solution (potassium acetate buffer solution) and
stored at -20ºC.23 The GCF samples were collected at
the baseline and after 2, 6, 10, and 20 weeks from all
the groups. All the samples were collectively analyzed
for β-glucuronidase activity.

Treatment protocol
All the patients included in the study received oral
hygiene instructions. The patients with periodontitis
in groups 1 and 3 received nonsurgical periodontal
treatment, which comprised instr uctions about
oral hygiene and supragingival and subgingival
debridement (SRP). The treatment took, on average,
four sessions of 40 min for 2 weeks.20 The SRP was
performed with manual instruments (Gracey Curettes)
and a Biosonic ultrasonic dental scaler. Reevaluations
were performed after 2, 6, 10, and 20 weeks, and oral
hygiene reinforcement was done at each recall visit.

Laboratory studies
Estimation of βG concentration in the GCF: The βG
concentration in the GCF was estimated by using the
reagent kit supplied by Sigma Aldrich diagnostics®,
and an spectrophotometric analysis was done using
an autoanalyzer. The method used was based upon the
modified procedure.24,25 A phenolpthalein standard
curve was constructed into 10 concentrations of
phenolphthalein ranging from 100 to 10 µg and were
plotted against absorbance at 540nm (Figure 1) βG acts
on phenolphthalein mono β glucuronic acid, liberating
the free phenolphthalein. The rate of hydrolysis of

Experimental parameters
Determination of periodontal status
To determine the clinical periodontal status, probing
depths (PD) and the clinical attachment level (CAL)
were measured, and the plaque index (PI) and gingival
index (GI) scores were recorded.21,22 These data were
taken from the whole mouth for all teeth at four sites,
40
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Table 2. The level of β-glucuronidase in gingival crevicular fluid of all groups of treatment
GROUPS

BASELINE
2
Level of β-glucuronidase in GCF (IU)
1
1480 ± 97.97
980 ± 2259.1
2
1780 ± 258.1
400 ± 779.7
3
1780 ± 260
480 ± 1122.3

TIME (weeks)
6

10

20

350 ± 48.1
225 ± 408.5
0±0

955 ± 399.9
1590 ± 1093.5
1135 ± 544.3

1105 ± 1146.7
1250 ± 59.5
1780 ± 160

Group 1= scaling and root planing; Group 2= systemic doxycycline; Group 3= systemic doxycycline with scaling and root
planing. Differences of the clinical parameters measurement are shown in in mean ± SD.

phenolphthalein glucoronidase serves to assay the
concentration of βG.9 The liberated phenolphthalein
is estimated by the red color it gives at alkaline pH.
Phenolphthalein glucuronide has hardly any absorption
at the same pH.9
Statistical Analysis
The statistical test performed to analyze the results
was a Student’s t-test since all samples had a normal
distribution. A Student’s t-test for independent
variables was applied to compare groups 1, 2, and
3. The differences within groups were analyzed by
a one-way analysis of variance (ANOVA). When the
difference was significant, the groups were analyzed
by Tukeys HSD test bilaterally. The level of statistical
significance was established (p≤0.05). The means and
standard deviations were given to describe values.

(p ≤0.01) and was not significant at 20 weeks (p≥0.05).
However, when SRP + doxycycline were used, the GCF
βG level decreased significantly over the entire study
period (p≤0.001). In Table 2, when comparing groups
1 (SRP alone) and 2 (Doxycycline alone), the GCF βG
level was reduced significantly at 2, 6, and 10 weeks
(p≤0.05) and was not significant at 20 weeks. When
the SRP alone and doxycycline alone groups were
compared with the SRP + doxycycline group, the GCF
βG level was reduced significantly over the entire recall
visit period (p≤0.05 and p≤0.001, respectively).

DISCUSSION

Clinical Findings
The mean values of clinical parameters for all the groups
at baseline and 2, 6, 10, and 20 weeks are shown in
Table 1. The periodontal condition of groups 1, 2, and 3
markedly improved between the baseline and the recall
visits at 2, 6, 10, and 20 weeks (p≤0.001). However, the
SRP + doxycycline group showed a significantly greater
reduction in PD and gain in the CAL when compared
with the SRP alone and doxcycline alone groups at 10 at
20 weeks (p≤0.001, p≤0.05, and p≤0.05, respectively). A
significant reduction in the PI & GI scores of all groups
(p≤0.001) was observed, with significant differences
detectable between them over the entire study period
except in group 2, in which doxycycline alone was used
(p≥0.05) at 20 weeks.

The present study was designed to evaluate the
efficacy of doxycycline as an adjunct to SRP in chronic
periodontitis patients. GCF has a widely accepted
diagnostic potential. Although the GCF analysis
performed on absorbent paper points is a frequently
used method for evaluation, future studies should be
standardized and a consensus should be reached on the
methodological details, including data presentation.10
The samples collected for this study were kept at
-20ºC. The freezing time for all the samples in this
study was similar (collected at the baseline and 2, 6,
10, and 20 weeks), and the evaluation of the samples
therefore produced meaningful results. However,
certain limitations could not be overcome, such as the
choice of collection device, length of collection time,
number of sample repetitions.26-28 It is a known fact
that the amount of GCF collected varies from site to
site, and hence the volume collected differs. In this
study, we addressed this issue by standardizing the
time of collection to 30 seconds, yet the volume of fluid
collected differed.

Laboratory Findings
The mean βG levels in the GCF for all groups for the
entire study period are given in Table 2. All the groups
had a similar GCF βG level at the baseline (p≥0.05).
When SRP alone was used, the GCF βG levels were
reduced significantly at the 2 and 6 week recall visits
(p≤0.05), with no significant reduction at 10 and 20
weeks. When doxycycline alone was used, the GCF βG
level was reduced significantly at 2, 6, and 10 weeks

The study presented significant improvements in
clinical parameters in all the experimental groups. At
the end of 2, 6, 10, and 20 weeks, this improvement
was maintained mainly because of the efficient SRP
and proper compliance. SRP therapy causes a resolution
of inf lammatory response and a cessation of the
progression of periodontal disease and hence results
in a reduction of pocket depth and a relative gain in
clinical attachment.11 Following doxycycline alone,

RESULTS
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relatively no significant reduction was observed in the
clinical parameters at 20 weeks. This may be due to
several factors that are associated with the failure of
systemic antibiotics in the treatment of periodontitis.
These factors include patient compliance, incorrect
dosage or duration of the agent, poor absorption, or
poor distribution of the agent in the patient. In the
present study, patient compliance and improper dosage
were ruled out, as the patients were reinforced with
proper oral hygiene instructions on every recall visit.

microbial virulence factors and also to the lytic effect
of more pathogenic subgingival bacteria on host cells
leading to an intense host enzyme release.36
The present investigation demonstrated that the βG
levels in chronic periodontitis patients in the absence
of any treatment were significantly raised as compared
to those in patients receiving treatment. This is in
agreement with the findings who reported that a
comparison of the baseline and 2-week post-therapy
data for the entire population of his study indicated that
conservative periodontal therapy tended to decrease βG
levels in the GCF.32 This study is also in accordance
with the study that examined the effect of SRP on the
levels of βG in GCF over a 24-week period and showed
that βG significantly decreased following SRP.35 In the
present study, following SRP, the βG levels decreased
significantly at 6 weeks (p≤0.01), but not at 10 and 20
weeks. This may be due to poor patient compliance in
spite of repeated reinforcements.

The result of the present study showed that the use
of doxycycline in combination with SRP in chronic
periodontitis patients provided a better clinical
improvement (p≤0.001) beyond that obtained by
SRP therapy alone or doxycycline alone. Previous
studies have documented the effectiveness of systemic
doxycycline on clinical parameters and on subgingival
microbiota. 29 Doxycycline has several advantages
over other drugs of its group. These include low
dosage frequency, prolonged serum half life, the
decreased effect of food on absorption, and decreased
gastrointestinal effects.30 It is a potent metalloproteinase
inhibitor. 31 Hence, the improvement in clinical
parameters in group 4 is not only associated with the
effectiveness of nonsurgical periodontal therapy but
also to the beneficial effect of doxycycline.

In the present study, after SRP + doxycycline,
the GCF βG levels showed a marked reduction
throughout the study period. This reduction was highly
significant (p≤0.001) when compared with SRP alone or
doxycycline alone. The decreased enzyme levels may
be due to the nonsurgical periodontal therapy (SRP and
oral hygiene instructions), which causes a reduction in
bacterial load in the periodontal environment.11 Also,
the added effect of doxycycline in downregulating the
host collagenases, thereby reducing the enzyme levels,
may account for the decreased GCF βG levels.17 This
study demonstrated that the GCF βG levels in the only
SRP and only doxycycline groups tended to increase
at 10 and 20 weeks compared to the levels at 6 weeks,
whereas the GCF βG levels in the SRP + doxycycline
group continued to decrease over 20 weeks. This
indicates the usefulness of doxycycline as an adjunct
to nonsurgical periodontal therapy over an extended
period of time.

The interpretations of the present study with regards to
GCF βG levels were 1) that the systemic doxycycline
therapy alone seemed to result in no or minimal effect
on βG levels as compared to SRP and 2) that the positive
effects in the SRP + doxycycline-treated quadrants,
beyond those achieved with traditional SRP, could be
ascribed to the adjuvant effect of drug therapy. To our
knowledge, comprehensive studies of changes in βG
levels during and after the systemic administration of
antibiotics have not been performed.
The findings of the present study confirmed the
relationship between βG and periodontal disease, since
increase enzyme activity in GCF was observed when
clinical periodontal destruction was present. This is
in accordance with three previous studies.23,33,34 Our
data further show that when GCF was analyzed for
the presence and levels of βG activity, the presence of
detectable levels of βG was shown in all the subjects.
However, the diseased patients at the baseline presented
higher enzyme activity than the periodontally treated
patients. Therefore, these findings support the previous
studies, suggesting a role for increased host-originated
βG in the pathogenesis of periodontal disease.10,35

It identified that βG as a potential diagnostic marker of
periodontitis was present in GCF.1 It showed relatively
elevated levels of βG in GCF to various thresholds of
increased probing depth or probing attachment loss.36
The relative risk of disease progression when elevated
levels of the enzyme were present ranged from 6 to
14 times. Their analysis reported data for the patients,
but not for the individual sites. Nevertheless, our study
emphasizes the association of a prominent influx of
PMN cells into the crevice (as a measure of the intensity
of the acute inflammatory response) to destructive
periodontitis. Though the biochemical analysis of βG
holds promise for the early detection of periodontal
disease and the evaluation of treatment outcome,
further studies must determine the longitudinal
relationship of GCF βG activity to disease progression.

As indicated in previous studies conducted on various
GCF components, including enzymes, the highest GCF
βG activity was found in patients with disease when no
treatment was initiated.10,31-35 This increase in βG can
be attributed to the hyperactive state and pronounced
response of PMN as a consequence of the severity of
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CONCLUSION
The findings of the present study confirm the usefulness
of doxycycline as an adjunct to nonsurgical therapy in
reducing GCF βG levels and the clinical parameters.
Our results demonstrate a correlation between GCF
βG activity and periodontal clinical parameters. The
study demonstrates the role of βG in the progression
of periodontal disease and in determining the outcome
of treatment.
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